Predictors of antibiotic prescription for upper respiratory infections in cancer patients

癌症患者上呼吸道感染抗生素处方预测因素

阅读:1

Abstract

BACKGROUND: Limited data regarding predictors of antibiotic prescription for acute upper respiratory infections (URI) are available for ambulatory patients with cancer. METHODS: Adult cancer patients with URI who presented to the Urgent Care Center or Symptom Care Clinic (SCC) and had a respiratory pathogen panel (RPP) between September 1, 2019 and March 11, 2020, were evaluated. Patients were dichotomized by receipt of antibiotic prescription (yes vs no). Demographics, cancer treatment, URI characteristics, and URI management were compared by Student's t test or Mann-Whitney U test and χ(2) or Fisher's exact test as appropriate. Logistic regression was performed to evaluate predictors of antibiotic prescription. RESULTS: Of 552 patients, 384 (69.6%) received cancer treatment within 30 days of the URI, and 377 (68.3%) had a positive RPP result. Antibiotics were prescribed in 156 (28.3%) patients, and 26/156 (16.7%) were appropriate. Multivariate logistic regression showed that predictors of antibiotic prescribing included SCC visit location (odds ratio (OR) 2.09, 95% confidence interval (CI) 1.30-3.38), symptom duration >7 days (OR 2.29, 95% CI 1.26 - 4.17), earache (OR 9.30, 95% CI 3.47 - 24.93), sinus symptoms (OR 2.64, 95% CI 1.53 - 4.56), negative RPP result (OR 1.88, 95% CI 1.18 - 2.98), and negative RPP result for influenza (OR 3.31, 95% CI 1.53 - 7.16). CONCLUSIONS: Almost one-third of outpatients at a single cancer center were prescribed antibiotics for URI with only 16.7% being appropriate. Getting real-time RPP results can be helpful to optimize antibiotic prescribing. Understanding risk factors for antibiotic prescribing in ambulatory cancer patients with URI may better direct antimicrobial stewardship efforts.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。